How Can We Help?
Zavegepant, sold under the brand name Zavzpret, is a medication used for the treatment of migraine.[1] Zavegepant is a calcitonin gene-related peptide receptor antagonist.[1] It is sprayed into the nose.[1] It is sold by Pfizer.[1]
The most common adverse reactions include taste disorders, nausea, nasal discomfort, and vomiting.[1]
Zavegepant was approved for medical use in the United States in March 2023.[1][2][3][4]
Medical uses
Zavegepant is indicated for the acute treatment of migraine with or without aura in adults.[1][5][6]
References
- ^ a b c d e f g h "Zavzpret- zavegepant spray". DailyMed. 9 March 2023. Retrieved 25 August 2023.
- ^ "Drug Approval Package: Zavzpret". U.S. Food and Drug Administration (FDA). 3 April 2023. Retrieved 25 August 2023.
- ^ "Pfizer's Zavzpret (Zavegepant) Migraine Nasal Spray Receives FDA Approval" (Press release). 10 March 2023.
- ^ Dhillon S (June 2023). "Zavegepant: First Approval". Drugs. 83 (9): 825–831. doi:10.1007/s40265-023-01885-6. PMC 10209931. PMID 37227596.
- ^ Khan ZZ, Ahmed U, Shahzad F, Ali M, Tousif K, Ahmed U, et al. (July 2023). "Safety and Efficacy of Zavegepant in Treating Migraine: A Systematic Review". Cureus. 15 (7): e41991. doi:10.7759/cureus.41991. PMC 10428082. PMID 37593294.
- ^ Martirosov AL, Giuliano C, Shupp M, Channey S, Kale-Pradhan PB (October 2023). "Zavegepant Intranasal Spray for Migraines". The Annals of Pharmacotherapy: 10600280231209439. doi:10.1177/10600280231209439. PMID 37897226. S2CID 264543368.
Further reading
- Croop R, Madonia J, Stock DA, Thiry A, Forshaw M, Murphy A, Coric V, Lipton RB (October 2022). "Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial". Headache. 62 (9): 1153–1163. doi:10.1111/head.14389. PMC 9827820. PMID 36239038.
- Noor N, Angelette A, Lawson A, Patel A, Urits I, Viswanath O, et al. (2022). "A Comprehensive Review of Zavegepant as Abortive Treatment for Migraine". Health Psychology Research. 10 (3): 35506. doi:10.52965/001c.35506. PMC 9239361. PMID 35774914.
- Scuteri D, Tarsitano A, Tonin P, Bagetta G, Corasaniti MT (November 2022). "Focus on zavegepant: the first intranasal third-generation gepant". Pain Management. 12 (8): 879–885. doi:10.2217/pmt-2022-0054. PMID 36189708. S2CID 252681912.
External links
- Clinical trial number NCT04571060 for "Randomized Trial in Adult Subjects With Acute Migraines" at ClinicalTrials.gov
- Clinical trial number NCT03872453 for "Acute Treatment Trial in Adult Subjects With Migraines" at ClinicalTrials.gov
Recent Comments